The influence of body size on the pharmacodynamic and pharmacokinetic response to clopidogrel and prasugrel: A retrospective analysis of the FEATHER study.

Joseph A Jakubowski, Dominick J Angiolillo, Chunmei Zhou, David S Small, Brian A Moser, Jurrien M Ten Berg, Patricia B Brown, Stefan James, Kenneth J Winters, David Erlinge

Research output: Contribution to journalArticlepeer-review

16 Citations (SciVal)

Abstract

Patients treated with clopidogrel who have higher body size exhibit greater platelet reactivity than patients with lower body size. In a retrospective analysis of the FEATHER trial, we examined the relationship between platelet response to thienopyridines clopidogrel 75mg (Clop-75), prasugrel 5mg (Pras-5), and prasugrel 10mg (Pras-10) using 3 body size indices: body weight (BW), body mass index (BMI), and body surface area (BSA). Relationships were assessed as continuous variables and as 4 incremental body size groups.
Original languageEnglish
Pages (from-to)552-557
JournalThrombosis Research
Volume134
Issue number3
DOIs
Publication statusPublished - 2014

Subject classification (UKÄ)

  • Cardiac and Cardiovascular Systems

Fingerprint

Dive into the research topics of 'The influence of body size on the pharmacodynamic and pharmacokinetic response to clopidogrel and prasugrel: A retrospective analysis of the FEATHER study.'. Together they form a unique fingerprint.

Cite this